The Drug Enforcement Administration (DEA) has expressed concern that 'aggressive marketing practices' by telehealth companies may be contributing to excessive prescriptions for medications used to treat attention deficit hyperactivity disorder (), according to a letter from the agency. While the letter does not mention specific companies, it is believed to refer to telehealth companies such as Cerebral Inc. and Done Global Inc., whose prescribing practices have reportedly been under investigation by the DEA after blitzing social media with online adverts including and . This decision follows a more than doubling in Adderall prescriptions of more than 10% per year in 2021 through to October 2022, after a roughly 5% annual increase in the three years prior, according to data from research firm IQVIA.
Load More
Load More